Cash flow is returning

Big beat

Nordic non-life insurance - Q2 reporting wrap

Positive order momentum, but long tail

Attractive valuation despite negative revisions

Better PTP from non-reccuring items

Nordic non-life Q2e: A double tailwind

FX tailwind drives revisions

Analyst Day: On track for '27 targets, but cautious on AI

Evolution AB: 1 director

A director at Evolution AB bought 100,000 shares at 671.272SEK and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

NRC Group ASA: 1 director

A director at NRC Group ASA bought 120,000 shares at 6.000NOK and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

Nordic non-life insurance – Q1 reporting wrap

Orders picking up

Insurance trip: 16 insurers in three days

Non-life have price increases > inflation in all markets, most in Norway. Life insurance growth with rapid growth & dividend payments. Prefer ALMB, Sampo, Solid, Tryg among non-life; STB for life

Improvements in Norway and Sweden

Important year coming up

Tryg AS: 2 directors

Two Directors at Tryg AS sold 65,000 shares at between 149.720DKK and 149.964DKK. The significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...

Tryg (Buy, TP: DKK185.00) - Earnings momentum still solid

Through both favourable weather and narrowing credit spreads, Q1 PTP was 48% higher YOY. Recent repricing efforts continue to take effect, as seen in a 0.3%-points improved underlying claims ratio YOY, although portfolio rebalancing weighed somewhat on growth. Supported by an outlook for abating motor claims pressure, we continue to find the investment case favourable. Having made limited EPS revisions for 2026–2027e, we reiterate our BUY and DKK185 target price.

A safer place to be

PTP beat from financials, UW inline

PTP beat from better financials, UW inline or a tad better. Reiterate '27 guidance and '25 premium growth from private/SMEs. Stock to outperform 1-3%; cons.est.rev. minor; strong read-x to GJF